Data gathered: January 10
AI Stock Analysis - Tarsus Pharmaceuticals (TARS)
Analysis generated January 7, 2025. Powered by Chat GPT.
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic treatments. Known for its innovative pipeline and strategic approach, Tarsus is positioned in a growing market, driving interest due to its recent performance metrics and expansion activities.
Stock Alerts - Tarsus Pharmaceuticals (TARS)
 |
Tarsus Pharmaceuticals | January 7 Price is down by -5.4% in the last 24h. |
|
Tarsus Pharmaceuticals | December 18 Price is up by 6.1% in the last 24h. |
|
Tarsus Pharmaceuticals | December 11 Price is up by 5.6% in the last 24h. |
|
Tarsus Pharmaceuticals | December 2 Price is down by -5.1% in the last 24h. |
Alternative Data for Tarsus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 24 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 57,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 87 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 460 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,088 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 686 | Sign up | Sign up | Sign up |
| Twitter Followers | 605 | Sign up | Sign up | Sign up |
| Twitter Mentions | 18 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 327 | Sign up | Sign up | Sign up |
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
| Price | $55.24 |
| Target Price | Sign up |
| Volume | 904,960 |
| Market Cap | $2.11B |
| Year Range | $21.54 - $56.2 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Franklin Resources Inc.January 1 - ETF Daily News |
|
Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High – Should You Buy?December 30 - ETF Daily News |
 |
Tarsus Pharmaceuticals stock soars to 52-week high of $56.84December 30 - Investing.com |
|
Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) and CG Oncology (NASDAQ:CGON)December 27 - ETF Daily News |
|
Geode Capital Management LLC Buys 62,555 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)December 27 - ETF Daily News |
 |
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit RunDecember 26 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 48M | 58M | -9.9M | -23M | -25M | -0.610 |
| Q2 '24 | 41M | 59M | -18M | -33M | -33M | -0.880 |
| Q1 '24 | 28M | 52M | -24M | -36M | -38M | -1.010 |
| Q4 '23 | 13M | 43M | -30M | -42M | -41M | -1.310 |
| Q3 '23 | 1.9M | 30M | -28M | -39M | -39M | -1.280 |
Insider Transactions View All
| LINK WILLIAM J PHD filed to sell 5,021 shares at $26. August 14 '24 |
| Farrow Jeffrey S filed to sell 18,136 shares at $27.5. June 20 '24 |
| Neervannan Seshadri filed to sell 64,767 shares at $30.6. March 19 '24 |
| Whitfield Dianne C. filed to sell 34,181 shares at $30.6. March 19 '24 |
Similar companies
Read more about Tarsus Pharmaceuticals (TARS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Tarsus Pharmaceuticals?
The Market Cap of Tarsus Pharmaceuticals is $2.11B.
What is the current stock price of Tarsus Pharmaceuticals?
Currently, the price of one share of Tarsus Pharmaceuticals stock is $55.24.
How can I analyze the TARS stock price chart for investment decisions?
The TARS stock price chart above provides a comprehensive visual representation of Tarsus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tarsus Pharmaceuticals shares. Our platform offers an up-to-date TARS stock price chart, along with technical data analysis and alternative data insights.
Does TARS offer dividends to its shareholders?
As of our latest update, Tarsus Pharmaceuticals (TARS) does not offer dividends to its shareholders. Investors interested in Tarsus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tarsus Pharmaceuticals?
Some of the similar stocks of Tarsus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.